BackAtara Biotherapeutics Overview

Atara Biotherapeutics Long Term Debt

Atara Biotherapeutics's long-term debt is $9.1M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$9.08M
66.02% YoYΔ $-17.63M vs prior year quarter

Peer average

Loading

Atara Biotherapeutics Long Term Debt History

Loading

Atara Biotherapeutics vs. peers: Long Term Debt Comparison

Loading

Atara Biotherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Atara Biotherapeutics (ATRA) FAQ

As of the most recent data (March 2026), ATRA shows a long-term debt of $9.1M. That compares with $27M in the prior-year period — down 66.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ATRA's long-term debt is now $9.1M (was $27M) — a 66.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Atara Biotherapeutics is outperforming or lagging.

Tracking ATRA's long-term debt over time shows whether Atara Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $9.1M That compares with $27M in the prior-year period — down 66.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Atara Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $9.1M) with ownership activity and broader fundamentals.

Atara Biotherapeutics's long-term debt is $9.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.